Tada,

Just to put it in perspective. the three recent cardiovascular outcomes trial in diabetics all achieved only 13-14% relative risk reduction (RRR) in 3-point MACE. These three recent trials were for glucose lowering medications in the SGLT2 inhibitor class (empaglifozin/EMPA-REG OUTCOME trial and canagliflozin/CANVAS trial) and the GLP1 receptor agonist liraglutide (LEADER trial). These recent trials are considered a huge success, since reducing cardiovascular risk in diabetics has long been a challenge. If indeed BETonMACE shows a RRR of 30% or greater in diabetics, then this will be a tremendous achievement. Furthermore, if the BETonMACE 3-point MACE RRR shows a 55-77% RRR (as seen in the post-hoc analysis of SUSTAIN/ASSURE for 5-point MACE), then this will be likely regarded as one of the most beneficial drugs in the history of cardiovascular medicine, in my opinion. Tick tock. Tick tock. 

BearDownAZ